Oral semaglutide significantly reduces low-density lipoprotein cholesterol level

Statement of ethics

The study protocol was reviewed and approved by the review board of Hidaka Hospital (approved reference: 336) on 17 July 2021. The research complies with the guidelines for human studies in accordance with the World Medical Association Declaration of Helsinki. Written informed consent was obtained from the patient for publication of this manuscript and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Conflict of interest

None of the authors have any potential conflicts of interest associated with this case presentation.

Comments (0)

No login
gif